Clinician's overview of platelet support

Area of Science:

• Hematology
• Oncology
• Geriatrics

Background:

• Acute myeloblastic leukaemia (AML) and myelodysplastic syndromes (MDS) affect elderly populations.
• Treatment decisions for elderly patients require careful consideration of comorbidities and support needs.

Purpose of the Study:

• To evaluate the feasibility and outcomes of long-term supportive care for elderly patients with AML or MDS.
• To assess the resource utilization, specifically platelet transfusions, in elderly AML/MDS patients.

Main Methods:

• Retrospective analysis of 48 patients over 55 years old with AML or MDS (≥10% blasts) over a 2-year period.
• Comparison of treatment strategies: intensive chemotherapy versus supportive care alone.
• Documentation of platelet transfusion requirements for both groups.

Main Results:

• Supportive care alone was a feasible option for elderly AML/MDS patients.
• Patients receiving supportive care alone required a mean of 380 units of platelets each.
• Intensive chemotherapy required a mean of 48 units of platelets per course.

Conclusions:

• Long-term supportive care is a viable management strategy for elderly patients with acute myeloblastic leukaemia or myelodysplastic syndrome.
• Elderly patients with dysplasia may experience bleeding at a higher threshold.
• Unintentional steroid use for transfusion reactions may increase the risk of fungal infections in this vulnerable group.